Comorbidity and clinical assessment in geriatric patients with cancer

Yıl 2007, Cilt: 22 Sayı: 4, 192 - 196, 01.05.2007

Savaş Tuna

Öz

The developments in preventive and curative medicine, improvement of life conditions and nutrition have rapidly increased the number of elderly people in the general population. Approximately half of all cancer events occur in people 65 years and older. Cancer is the most second cause of all death in this patient population. Aging is a personal phenomenon and physiology may not necessarily be parallel to the chronological age. Elderly people are known to have a higher incidency of both cancer and comorbidity. Cancer patients age 70 and older have the least 3 comorbidities. Decision-making for cancer treatment in geriatric population must first evaluate personal functional capacity. Elderly people are not only older adults; they have unique physiologic features and pharmacological response patterns. Life expectancy and chemotherapy complication risks may be determined by comprehensive geriatric assessment and results of this assessment provide better judgment in the choice of standard or palliative treatment.

Anahtar Kelimeler

Comorbidity, Aged, Geriatric Assessment, Neoplasms

Kanserli geriatrik hastalarda komorbidite ve klinik değerlendirme

Öz

Koruyucu ve tedavi edici tıptaki gelişmeler ile beslenme ve hayat şartlarındaki iyileştirmeler sonucu genel nüfus içindeki yaşlı insan sayısı hızla artmaktadır. Tüm kanser vakalarının %50'si 65 yaş üzerinde görülür ve 65 yaş üzerinde ölüm nedenleri arasında kanser ikinci sıradadır. Yaşlanma kişisel bir fenomendir ve takvim yaşıyla paralellik göstermeyebilir. Yaşlılarda kanser ve komorbidite insidansının da yüksek olduğu bilinmektedir. Yetmiş yaş üzerindeki kanser hastalarının yarıdan fazlasında en az üç komorbidite vardır. Geriatrik nüfusta kanser tedavisi planlanırken öncelikle bireysel fonksiyonel kapasite iyi değerlendirilmelidir. Yaşlılar, erişkinlerin sadece yaşça büyükleri olmayıp, daha farklı fizyolojik özelliklere ve farmakolojik yanıt biçimine sahiptirler. Kapsamlı geriatrik değerlendirme ile elde edilen bilgiler sayesinde yaşam beklentisi öngörüleri ve kemoterapi komplikasyonları için yüksek riskli hastalar saptanabilir. Bu da standart ya da palyatif tedavi kararına olanak sağlar.

Anahtar Kelimeler

Geriatrik onkoloji, kapsamlı geriatrik değerlendirme, komorbidite

Kaynakça

• 1. Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recom-mendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005;55(3):241-52.
• 2. Gosney MA. Clinical assessment of elderly people with cancer. Lancet Oncol 2005;6(10):790-7.
• 3. Audisio RA, Ramesh H, Longo WE, Zbar AP, Pope D. Preoperative as-sessment of surgical risk in oncogeriatric patients. Oncologist 2005;10(4):262-8.
• 4. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a metaanalysis of controlled trials. Lancet 1993;342(8878):1032-6.
• 5. Moore AA, Siu AL. Screening for common problems in ambulatory elderly: clinical confirmation of a screening instrument. Am J Med 1996;100(4):438-43.
• 6. Lachs MS, Feinstein AR, Cooney LM Jr, Drickamer MA, Marottoli RA, Pannill FC, et al. A simple procedure for general screening for functional dis-ability in elderly patients. Ann Intern Med 1990;112(9):699- 706.
• 7. Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001;49(12):1691-9.
• 8. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5(3):224-37.
• 9. Monfardini S, Ferrucci L, Fratino L, del Lungo I, Serraino D, Zagonel V. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77(2):395-401.
• 10. Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005;41(18):2887-95.
• 11. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a pro-spective cohort study. J Clin Oncol 2002;20(1):42-51.
• 12. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003;21(3):433-40.
• 13.Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is as-sociated with a reduced incidence of primary breast carcinoma. Cancer 2005;103(6):1122-8.
• 14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Ex-amination Survey. JAMA 2002;287(3):356-9.
• 15. Alibhai SM, Leach M, Tomlinson G, Krahn MD, Fleshner N, Holowaty E, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005;97(20):1525-32.